Comparison of the efficacy and safety of conventional transarterial chemoembolization with and without drug‐eluting beads embolization for the treatment of unresectable large hepatocellular carcinoma

Aim Hepatocellular carcinoma (HCC) has a poor prognosis. Moreover, large HCCs have been commonly observed. We aimed to evaluate the efficacy and safety of drug‐eluting beads transarterial chemoembolization (DEB‐TACE) combined with conventional TACE (cTACE) for the treatment of patients with unresect...

Full description

Saved in:
Bibliographic Details
Published in:Hepatology research 2021-04, Vol.51 (4), p.482-489
Main Authors: Chen, Shiguang, Yu, Wenchang, Zhang, Kongzhi, Liu, Weifu, Chen, Chuanben
Format: Article
Language:English
Subjects:
Adverse events
Constipation
drug‐eluting beads
Embolization
epirubicin
gelatin sponge particle
Hepatocellular carcinoma
Liver cancer
Nausea
Patients
Response rates
transarterial chemoembolization
Vomiting
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aim Hepatocellular carcinoma (HCC) has a poor prognosis. Moreover, large HCCs have been commonly observed. We aimed to evaluate the efficacy and safety of drug‐eluting beads transarterial chemoembolization (DEB‐TACE) combined with conventional TACE (cTACE) for the treatment of patients with unresectable large HCCs (main tumor ≥5 cm in diameter) compared with cTACE alone. Methods A retrospective matched cohort study was performed on consecutive patients with unresectable large HCCs who underwent TACE as the initial treatment at the Fujian Medical University Cancer Hospital from May 2017 and March 2019. Fifty‐five patients who underwent DEB‐TACE combined with cTACE were compared with a case‐matched control group of 110 patients who received cTACE alone. We compared the tumor response at 1 and 3 months after TACE, time to progression (TTP), and adverse events between the groups. Results The objective response rate was higher for the DEB‐TACE combined with cTACE group than for the cTACE alone group at 1 (39 of 55 [70.9%] vs. 57 of 110 [51.8%], p = 0.019) and 3 months (27 of 43 [62.8%] vs. 31 of 71 [43.7%], p = 0.048) post‐treatment. The DEB‐TACE combined with cTACE group also had a significantly longer median TTP than that of the cTACE group (7.2 vs. 5.3 months, p = 0.039). Compared with the cTACE group, occurrences of abdominal pain, nausea/vomiting, and constipation were significantly more frequent in the DEB‐TACE combined with cTACE group (p 
ISSN:1386-6346
1872-034X
DOI:10.1111/hepr.13620